Trump Counts On China To Deliver In The Day Of The Coronavirus
President dismisses fears of drug shortages as White House prepares to deliver US from dependence on China’s pharmaceutical manufacturing complex.
You may also be interested in...
Order sets a path for federal government to use its power as a purchaser of pharmaceuticals to nurture a high-tech domestic pharma manufacturing sector that would increase resilience against threats that could isolate the US from countries like China that are important nodes in the global manufacturing supply chain.
The Trump administration’s move to strengthen domestic manufacture of essential medicines raises a lot of questions – and industry’s ire.
US agency ensures pharmaceutical companies could manufacture critical medicines domestically even if cut off from China's API suppliers, while stockpiling pandemic medicines during pandemic with Baxter, Fresenius contracts.